.png)
.png)
State of the Discovery Nation report reveals the extent of sector's perfect storm
New report 'State of the Discovery Nation: Fostering a Dynamic, Sustainable Medicines Discovery Sector’ says the sector must work together to de-risk funding in medicines discovery and attract more investors.
BIA teams up with top UK engineering biology stakeholders to champion the UK at SynBioBeta 2024
BIA is gearing up for a prominent presence at SynBioBeta 2024, the world's leading conference for engineering biology. The BIA is leading a coalition of UK stakeholders to showcase the dynamism and innovation of the UK's engineering biology companies from 6-9 May in San Jose, California.
Post-Brexit border paperwork and inspections postponed for life sciences sector
Importers of laboratory reagents and materials used in the manufacture of medicines in the UK’s life sciences sector have been given a six-month extension to make the necessary changes to their supply chains for new post-Brexit border paperwork and border inspections.
BIA responds to Spring Budget 2024: highlights for UK life sciences
Three highlights for UK life sciences: first, the new expert advisory panel for the HMRC is a smart way to maximise the efficiency of R&D tax relief support for life science innovators; secondly, Alan Marchington’s ICG winning the LIFTs scheme shows real movement to unlock pension funds for life sciences; thirdly, AstraZeneca’s investment in next-generation manufacturing in Speke and Cambridge shows the strength of our ecosystem.
Deep Biotech will deliver a more sustainable future, and BIA is its new voice
Deep Biotech encompasses innovative companies harnessing the power of engineering biology to tackle humanity's most pressing challenges, from environmental pollution to climate change. From cultivating meat without animals to crafting bio-based materials that replace harmful plastics, Deep Biotech offers a sustainable roadmap for a greener future.
Professor Sir Mene Pangalos wins Lifetime Achievement Award at the BIA’s Gala Dinner
Mene led AstraZeneca's pharmaceutical discovery and early development through a key period of growth and innovation and was a driving force for scientific excellence and collaboration. Joining the company in 2010, Mene transformed AstraZeneca’s approach to R&D, fostering deeper academic and industry partnerships, pioneering Open Innovation programmes, and building a culture that values truth-seeking in science.
Resilient UK biotech sector lands £1.8 billion investment in 2023
New report highlights sector's strength, investor confidence and long-term returns. London-quoted biotechs also continue to outperform UK and US markets over the long term, having made substantial gains during the pandemic that have not been lost.
BIA unveils new data: UK leads Europe in cell and gene therapy as sector makes significant strides
The UK is cementing its position as a global leader in cell and gene therapy, according to a new report released today by the UK BioIndustry Association (BIA), in collaboration with Citeline.
BIA reaches 600 member companies, announces new board and leadership restructure
The UK’s innovative trade association for life science and biotech companies, BioIndustry Association (BIA), today announces that it has reached 600 companies in membership for the first time ever, alongside new Board and staff appointments for 2024.
BIA announces its Charity Partnership for 2024 with RNID
BIA is thrilled to announce its charity partnership of the year for 2024 with RNID, the national charity supporting the 12 million people in the UK who are deaf, have hearing loss or tinnitus.